293 related articles for article (PubMed ID: 8724143)
21. Novel N-acetyl-Glycol-split heparin biotin-conjugates endowed with anti-heparanase activity.
Esposito E; Vlodavsky I; Barash U; Roscilli G; Milazzo FM; Giannini G; Naggi A
Eur J Med Chem; 2020 Jan; 186():111831. PubMed ID: 31740052
[TBL] [Abstract][Full Text] [Related]
22. Substrate specificity of heparanases from human hepatoma and platelets.
Pikas DS; Li JP; Vlodavsky I; Lindahl U
J Biol Chem; 1998 Jul; 273(30):18770-7. PubMed ID: 9668050
[TBL] [Abstract][Full Text] [Related]
23. Heparanase, heparin and the coagulation system in cancer progression.
Vlodavsky I; Ilan N; Nadir Y; Brenner B; Katz BZ; Naggi A; Torri G; Casu B; Sasisekharan R
Thromb Res; 2007; 120 Suppl 2():S112-20. PubMed ID: 18023704
[TBL] [Abstract][Full Text] [Related]
24. Periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung.
Ono K; Ishihara M; Ishikawa K; Ozeki Y; Deguchi H; Sato M; Hashimoto H; Saito Y; Yura H; Kurita A; Maehara T
Br J Cancer; 2002 Jun; 86(11):1803-12. PubMed ID: 12087470
[TBL] [Abstract][Full Text] [Related]
25. Design of an Ultralow Molecular Weight Heparin That Resists Heparanase Biodegradation.
Ham H; Xu Y; Haller CA; Dai E; Stancanelli E; Liu J; Chaikof EL
J Med Chem; 2023 Feb; 66(3):2194-2203. PubMed ID: 36706244
[TBL] [Abstract][Full Text] [Related]
26. Metastatic melanoma cell heparanase. Characterization of heparan sulfate degradation fragments produced by B16 melanoma endoglucuronidase.
Nakajima M; Irimura T; Di Ferrante N; Nicolson GL
J Biol Chem; 1984 Feb; 259(4):2283-90. PubMed ID: 6698965
[TBL] [Abstract][Full Text] [Related]
27. Suramin. A potent inhibitor of melanoma heparanase and invasion.
Nakajima M; DeChavigny A; Johnson CE; Hamada J; Stein CA; Nicolson GL
J Biol Chem; 1991 May; 266(15):9661-6. PubMed ID: 2033058
[TBL] [Abstract][Full Text] [Related]
28. Tumor metastasis-associated heparanase (heparan sulfate endoglycosidase) activity in human melanoma cells.
Nakajima M; Irimura T; Nicolson GL
Cancer Lett; 1986 Jun; 31(3):277-83. PubMed ID: 3719568
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity.
Yoshitomi Y; Nakanishi H; Kusano Y; Munesue S; Oguri K; Tatematsu M; Yamashina I; Okayama M
Cancer Lett; 2004 Apr; 207(2):165-74. PubMed ID: 15072825
[TBL] [Abstract][Full Text] [Related]
30. Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.
Cassinelli G; Lanzi C; Tortoreto M; Cominetti D; Petrangolini G; Favini E; Zaffaroni N; Pisano C; Penco S; Vlodavsky I; Zunino F
Biochem Pharmacol; 2013 May; 85(10):1424-32. PubMed ID: 23466421
[TBL] [Abstract][Full Text] [Related]
31. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins.
Wang L; Brown JR; Varki A; Esko JD
J Clin Invest; 2002 Jul; 110(1):127-36. PubMed ID: 12093896
[TBL] [Abstract][Full Text] [Related]
32. Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin.
Nasser NJ; Sarig G; Brenner B; Nevo E; Goldshmidt O; Zcharia E; Li JP; Vlodavsky I
J Thromb Haemost; 2006 Mar; 4(3):560-5. PubMed ID: 16460439
[TBL] [Abstract][Full Text] [Related]
33. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting.
Naggi A; Casu B; Perez M; Torri G; Cassinelli G; Penco S; Pisano C; Giannini G; Ishai-Michaeli R; Vlodavsky I
J Biol Chem; 2005 Apr; 280(13):12103-13. PubMed ID: 15647251
[TBL] [Abstract][Full Text] [Related]
34. Evidence that platelet and tumour heparanases are similar enzymes.
Freeman C; Browne AM; Parish CR
Biochem J; 1999 Sep; 342 ( Pt 2)(Pt 2):361-8. PubMed ID: 10455023
[TBL] [Abstract][Full Text] [Related]
35. A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity.
Takahashi H; Ebihara S; Okazaki T; Asada M; Sasaki H; Yamaya M
Br J Pharmacol; 2005 Oct; 146(3):333-43. PubMed ID: 16041398
[TBL] [Abstract][Full Text] [Related]
36. Evidence that sulphated polysaccharides inhibit tumour metastasis by blocking tumour-cell-derived heparanases.
Parish CR; Coombe DR; Jakobsen KB; Bennett FA; Underwood PA
Int J Cancer; 1987 Oct; 40(4):511-8. PubMed ID: 3666989
[TBL] [Abstract][Full Text] [Related]
37. Antitumor properties of a new non-anticoagulant heparin analog from the mollusk Nodipecten nodosus: Effect on P-selectin, heparanase, metastasis and cellular recruitment.
Gomes AM; Kozlowski EO; Borsig L; Teixeira FC; Vlodavsky I; Pavão MS
Glycobiology; 2015 Apr; 25(4):386-93. PubMed ID: 25367817
[TBL] [Abstract][Full Text] [Related]
38. Specific degradation of subendothelial matrix proteoglycans by brain-metastatic melanoma and brain endothelial cell heparanases.
Marchetti D
J Cell Physiol; 1997 Sep; 172(3):334-42. PubMed ID: 9284953
[TBL] [Abstract][Full Text] [Related]
39. The B16F10 cell receptor for a metastasis-promoting site on laminin-1 is a heparan sulfate/chondroitin sulfate-containing proteoglycan.
Engbring JA; Hoffman MP; Karmand AJ; Kleinman HK
Cancer Res; 2002 Jun; 62(12):3549-54. PubMed ID: 12068003
[TBL] [Abstract][Full Text] [Related]
40. Colorimetric heparinase assay for alternative anti-metastatic activity.
Ahn SC; Kim BY; Oh WK; Park YM; Kim HM; Ahn JS
Life Sci; 2006 Sep; 79(17):1661-5. PubMed ID: 16806278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
